Erlotinib in lung cancer - molecular and clinical predictors of outcome.
暂无分享,去创建一个
Lesley Seymour | Ming-Sound Tsao | Suzanne Kamel-Reid | L. Seymour | M. Tsao | A. Sakurada | K. Ding | Ni Liu | F. Shepherd | G. da Cunha Santos | S. Kamel‐Reid | J. Squire | Tong Zhang | Chang-Qi Zhu | J. Pater | J. Cutz | M. Daneshmand | P. Marrano | I. Lorimer | Keyue Ding | Frances A Shepherd | Jeremy Squire | Tong Zhang | Ni Liu | Paula Marrano | Gilda da Cunha Santos | Jean-Claude Cutz | M. Whitehead | Joseph Pater | A. Lagarde | Akira Sakurada | Chang-Qi Zhu | Ian Lorimer | Manijeh Daneshmand | Alain Lagarde | Frank Richardson | Marlo Whitehead | F. Richardson
[1] N. Hanna,et al. EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .
[2] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[3] Y. Kim,et al. Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[4] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[5] A. Hölscher,et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] R. Nicholson,et al. EGFR and cancer prognosis. , 2001, European journal of cancer.
[7] F. Khuri,et al. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. , 2006, Oncology.
[8] L. Tanoue,et al. Erlotinib in Previously Treated Non-Small-Cell Lung Cancer , 2007 .
[9] Andrew D. Yates,et al. Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.
[10] M Paesmans,et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis , 2002, European Respiratory Journal.
[11] Young Tae Kim,et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Shih-Feng Tsai,et al. High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan , 2004, Clinical Cancer Research.
[13] V Torri,et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Chan Zeng,et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Joseph Schlessinger,et al. Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor , 2002, Cell.
[16] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[17] D. Swinson,et al. Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer , 2004, British Journal of Cancer.
[18] E. Dmitrovsky,et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] William J. Gullick,et al. The erbB family of receptors and their ligands: multiple targets for therapy. , 2001 .
[20] C. Plass,et al. Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors , 2005, British Journal of Cancer.
[21] F. Shepherd,et al. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma. , 2000, Lung cancer.
[22] J. Rigas,et al. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] C. Arteaga. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. , 2002, Seminars in oncology.
[24] Takayuki Kosaka,et al. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.
[25] Elisa Rossi,et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.
[26] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] A. Marchetti,et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Dancey. Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow. , 2004, Cancer cell.
[29] Thomas J Lynch,et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. , 2004, Lung cancer.
[30] S. Toyooka,et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[32] C. Angeletti,et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] R. Herbst,et al. Targeting the epidermal growth factor receptor in non-small cell lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] Leah E. Mechanic,et al. Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[35] G. Gibson,et al. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. , 1993, British Journal of Cancer.
[36] A. Santoro,et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer , 2004, British Journal of Cancer.
[37] William Pao,et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] T. Utsunomiya,et al. Somatic Mutations of Epidermal Growth Factor Receptor in Colorectal Carcinoma , 2005, Clinical Cancer Research.
[39] Lesley Seymour,et al. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. , 2003, The Lancet. Oncology.
[40] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[41] H. Poulsen,et al. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.